

AD-A039 733

DEFENCE AND CIVIL INST OF ENVIRONMENTAL MEDICINE DOW--ETC F/G 6/15
THE EFFECT OF VASODILATOR DRUGS (RONIACOL AND PRISCOLINE) ON SK--ETC(U)
FEB 77 W S MYLES, S D LIVINGSTONE

UNCLASSIFIED

DCIEM-TR-77-X-7


NL

1 of 1
AD
A039733



END

DATE
FILMED
6-77



MICROCOPY RESOLUTION TEST CHART
NATIONAL BUREAU OF STANDARDS-1963-A


10

DCIEM Technical Report No. 77X7

(3)

ADA 039733

The Effect of Vasodilator Drugs (Roniacol and Priscoline) on Skin Temperatures and Blood Flow During Mild Cold Stress.



W.S. Myles

S.D. Livingstone

DDC
RECEIVED
MAY 23 1977
B

DISTRIBUTION STATEMENT A
Approved for public release
Distribution Unlimited

DEFENCE AND CIVIL INSTITUTE OF ENVIRONMENTAL MEDICINE
INSTITUT MILITAIRE ET CIVIL DE MEDECINE DE L'ENVIRONNEMENT

DDC FILE COPY

February, 1977

DCIEM Technical Report No. 77X7

The Effect of Vasodilator Drugs (Roniacol
and Priscoline) on Skin Temperatures and
Blood Flow During Mild Cold Stress.

W.S. Myles

S.D. Livingstone

Biosciences Division
Defence and Civil Institute of Environmental Medicine
1133 Sheppard Avenue West, P.O. Box 2000
Downsview, Ontario M3M 3B9

DEPARTMENT OF NATIONAL DEFENCE - CANADA

See 1473

TABLE OF CONTENTS

	Page
ABSTRACT	v
INTRODUCTION	1
METHODS	1
RESULTS	2
DISCUSSION	2
REFERENCES	4

ACCESSION for		
RTIS	White Section	<input checked="" type="checkbox"/>
DDC	Buff Section	<input type="checkbox"/>
UNANNOUNCED		<input type="checkbox"/>
JUSTIFICATION.....		
BY.....		
DISTRIBUTION/AVAILABILITY CODES		
Dist.	AVAIL. and/or	SPECIAL
A		

ABSTRACT

Two vasodilator drugs (Roniacol and Priscoline) were tested for their potential prophylactic effect in the prevention of cold-induced vasoconstriction in the hands of human subjects during exposure to mild cold stress. The drugs were administered as a single dose by mouth (300 mg Roniacol or 50 mg Priscoline) to nude subjects lying quietly for 90 minutes at 21°C. Skin temperatures were measured at the left middle finger, the left big toe and the abdomen, also, skin blood flow in the right middle finger was monitored. Neither Roniacol nor Priscoline had any effect on these measurements of skin temperature or skin blood flow as compared to similar measurements made in control (no drug) exposures. Because of these negative findings in nude subjects during mild cold stress, it is suggested that these drugs would provide no significant protection against cold hands for clothed individuals exposed to a more severe cold stress.

INTRODUCTION

Cold hands are a problem for those who work outdoors in cold weather. Cold-induced vasoconstriction reduces blood flow in the hands, causing loss of feeling and an impairment of manual dexterity. Heavy gloves or mittens are not a satisfactory solution to this problem since their use causes delicate hand manipulations to be extremely difficult to perform. Vasodilator drugs appear to be a possible pharmacological solution to the problem of cold hands and feet. These drugs have been used in the treatment of vascular diseases characterized by episodes of peripheral vasoconstriction (3,5). Mountaineers and skiers have also reported taking Roniacol (nicotin alcohol tartrate) or Priscoline (tolazfoline hydrochloride) in the belief that these drugs increase the flow of warm blood to the hands and feet, thereby preventing frostbite (1, 2, 4).

Since none of the available evidence presented in the literature is conclusive, the objective of the present study was to determine in a simple experiment whether a single dose of Roniacol or Priscoline can counteract cold-induced vasoconstriction of the extremities under controlled conditions and whether further detailed experiments are warranted to fully document and exploit any benefit of these drugs in this regard.

METHODS

Six male subjects, aged 20-35 years, were each exposed to an ambient temperature of 21°C and a relative humidity of 50% in a temperature-controlled room. The subjects wore shorts only and lay quietly on a mattress. Thermistor probes (Yellow Springs Instrument Co., Ohio) were attached to each subject via Beckman electrode collars at the following sites: the middle left finger, the left big toe and the abdomen. Skin blood flow in the middle right finger was recorded using the Beckman dynograph recorder with a type 9853 coupler in the voltage/pulse mode. This instrument consists of a small light source and a photoelectric cell which responds to light transmission through the skin, which, in turn, depends on the blood content of the skin. Temperature and blood flow were measured at the respective sites every ten minutes during each exposure.

Each subject was thus exposed three times at 21°C for 90 minutes. For the control exposure, no drug was given. On the other two occasions either Roniacol (300 mg dose) or Priscoline (50 mg dose) was administered orally after 30 minutes exposure, a time deemed sufficient to permit equilibrium of the subject's skin temperature with the ambient environment. The observation

period lasted for a further 60 minutes. The sequence of exposures was random and at least a week lapsed between any two exposures of the same subject to avoid any inter-experimental phenomena.

RESULTS

During the 90 minute cold exposure, the skin temperature of the finger and toe declined steadily to a stable level which was maintained for the last 30 minutes and which was only slightly greater than the temperature of the ambient air. At the same time, the skin temperature of the abdomen decreased by 1 to 2°C. There was no sign of drug-induced vasodilation, as would have been indicated by a rise in skin temperature, in the hour which followed administration of either Priscoline or Roniacol. Table 1 shows the average finger, abdomen and toe temperatures for the six subjects during the last 30 minutes of each exposure at 21°C. There was no difference in these average skin temperatures that could be attributed to the drug treatment.

Since the method of measuring skin blood flow used in these experiments does not yield quantitative values, the data for each individual subject has not been reproduced in this report. Figure 1 shows portions of a typical tracing. In each exposure, skin blood flow in the finger followed the trend indicated by skin temperature, that is, the amplitude of the signal (see Figure 1) decreased progressively with developing vasoconstriction and there was no sign of a reversal due to a drug-induced vasodilation.

DISCUSSION

Vasodilator drugs have been used in cold environments on the assumption that they protect against cold injury. Most anecdotal evidence suffers from the lack of an adequate control exposure in which no drug was administered. For example, in his account of the ascent of the north face of the Eiger (4), a well-known mountaineer reported that he ingested a large dose of Roniacol to prevent what he considered to be imminent frostbite to his feet. The fact that he did not sustain any subsequent tissue loss cannot be considered as a casual effect of the ingestion of the drug.

In the present study, the effect of Roniacol and Priscoline were compared against a control (no drug) exposure. The exposure conditions selected, 90 minutes at 21°C, represented a mild whole body cold stress for a nude (shorts only) individual who was lying quietly. As a result, skin temperature, particularly those of the fingers and toes, decreased due to vasoconstriction. Blood flow in the finger showed the same trend and neither Roniacol or

Priscoline, in the dosages administered, were able to induce vasodilation. Because of these negative findings, during mild cold stress, it is suggested that these drugs would provide no significant protection against cold hands for a clothed individual exposed to a more severe cold stress. Further detailed experiments to fully document and exploit the effect of these drugs in this regard are not warranted.

REFERENCES

- ADAMS-RAY, J. (1952). Pathophysiology of cold injuries. In "Cold Injury" Jos. Macy Fdn. p 139
- BONNINGTON, C. (1971). In "Annapurna, South Face". Appendix describing medical supplies. Cassell, Lond.
- FRIEND, D.G. (1964). Drugs for peripheral vascular disease. Clin. Pharmacol. Ther. 5:666-672.
- GILLMAN, P. and D. HASTON. (1966). In "Eiger Direct". Collins Lond. p 165
- WINSOR, T. (1967). Occlusive disease of the extremities. Medical treatment. Post grad. Med. 42: 195-202.

TABLE 1

THE EFFECT OF RONIACOL AND PRISCOLINE ON SKIN TEMPERATURES
DURING COLD EXPOSURE

Treatment	Average skin temperature ($^{\circ}\text{C}$)		
	Finger	Abdomen	Toe
No drug	24.3 \pm 0.6	31.2 \pm 0.5	22.4 \pm 0.3
Roniacol	22.6 \pm 0.4	31.5 \pm 0.3	22.2 \pm 0.4
Priscoline	23.4 \pm 0.8	30.5 \pm 0.6	21.4 \pm 0.2

Values are the means \pm (60 - 90 minutes) for 6 subjects. Individual skin temperatures at each site were compared using a Kruskal-Wallis test which gives a statistic which was then tested by the Chi Square method using two degrees of freedom. There was no significant difference between treatments.




Figure 1: Portions of a characteristic dynograph tracing extracted to illustrate skin blood flow in the finger at 30 min intervals during exposure of one subject at 21°C. Paper speed was 1 mm/sec. Vertical scale shows a pen deflection of 0.5mv/cm. The relative amplitudes at the indicated times demonstrates a reduction of skin blood flow, indicative of vasoconstriction.

Unclassified

Security Classification

DOCUMENT CONTROL DATA - R & D

(Security classification of title, body of abstract and indexing annotation must be entered when the overall document is classified)

1. ORIGINATING ACTIVITY (14) DCIEM-TR-77-X-7		2a. DOCUMENT SECURITY CLASSIFICATION Unclassified	
		2b. GROUP	
3. DOCUMENT TITLE (6) THE EFFECT OF VASODILATOR DRUGS (RONIACOL AND PRISCOLINE) ON SKIN TEMPERATURES AND BLOOD FLOW DURING MILD COLD STRESS.			
4. DESCRIPTIVE NOTES (Type of report and inclusive dates) (9) Technical Rept.			
5. AUTHOR(S) (Last name, first name, middle initial) (10) W.S. Myles, W.S. S.D. Livingstone, S.D.			
6. DOCUMENT DATE (11) February 1977		7a. TOTAL NO. OF PAGES 6	7b. NO. OF REFS 1
8a. PROJECT OR GRANT NO.		9a. ORIGINATOR'S DOCUMENT NUMBER(S) 77X7	
8b. CONTRACT NO. (12) 12p.		9b. OTHER DOCUMENT NO.(S) (Any other numbers that may be assigned this document)	
10. DISTRIBUTION STATEMENT Unlimited			
11. SUPPLEMENTARY NOTES		12. SPONSORING ACTIVITY DCIEM	
13. ABSTRACT <p>Two vasodilator drugs (Roniacol and Priscoline) were tested for their potential prophylactic effect in the prevention of cold-induced vasoconstriction in the hands of human subjects during exposure to mild cold stress. The drugs were administered as a single dose by mouth (300 mg Roniacol or 50 mg Priscoline) to nude subjects lying quietly for 90 minutes at 21°C. Skin temperatures were measured at the left middle finger, the left big toe and the abdomen, also, skin blood flow in the right middle finger was monitored. Neither Roniacol nor Priscoline had any effect on these measurements of skin temperature or skin blood flow as compared to similar measurements made in control (no drug) exposures. Because of these negative findings in nude subjects during mild cold stress, it is suggested that these drugs would provide no significant protection against cold hands for clothed individuals exposed to a more severe cold stress. *</p>			

406 986 JB

KEY WORDS

vasodilator drugs, cold induced vasodilation, nude subjects,
cold hands, blood flow

INSTRUCTIONS

1. **ORIGINATING ACTIVITY:** Enter the name and address of the organization issuing the document.
- 2a. **DOCUMENT SECURITY CLASSIFICATION:** Enter the overall security classification of the document including special warning terms whenever applicable.
- 2b. **GROUP:** Enter security reclassification group number. The three groups are defined in Appendix 'M' of the DRB Security Regulations.
3. **DOCUMENT TITLE:** Enter the complete document title in all capital letters. Titles in all cases should be unclassified. If a sufficiently descriptive title cannot be selected without classification, show title classification with the usual one-capital-letter abbreviation in parentheses immediately following the title.
4. **DESCRIPTIVE NOTES:** Enter the category of document, e.g. technical report, technical note or technical letter. If appropriate, enter the type of document, e.g. interim, progress, summary, annual or final. Give the inclusive dates when a specific reporting period is covered.
5. **AUTHOR(S):** Enter the name(s) of author(s) as shown on or in the document. Enter last name, first name, middle initial. If military, show rank. The name of the principal author is an absolute minimum requirement.
6. **DOCUMENT DATE:** Enter the date (month, year) of Establishment approval for publication of the document.
- 7a. **TOTAL NUMBER OF PAGES:** The total page count should follow normal pagination procedures, i.e., enter the number of pages containing information.
- 7b. **NUMBER OF REFERENCES:** Enter the total number of references cited in the document.
- 8a. **PROJECT OR GRANT NUMBER:** If appropriate, enter the applicable research and development project or grant number under which the document was written.
- 8b. **CONTRACT NUMBER:** If appropriate, enter the applicable number under which the document was written.
- 9a. **ORIGINATOR'S DOCUMENT NUMBER(S):** Enter the official document number by which the document will be identified and controlled by the originating activity. This number must be unique to this document.
- 9b. **OTHER DOCUMENT NUMBER(S):** If the document has been assigned any other document numbers (either by the originator or by the sponsor), also enter this number(s).
10. **DISTRIBUTION STATEMENT:** Enter any limitations on further dissemination of the document, other than those imposed by security classification, using standard statements such as:
 - (1) "Qualified requesters may obtain copies of this document from their defence documentation center."
 - (2) "Announcement and dissemination of this document is not authorized without prior approval from originating activity."
11. **SUPPLEMENTARY NOTES:** Use for additional explanatory notes.
12. **SPONSORING ACTIVITY:** Enter the name of the departmental project office or laboratory sponsoring the research and development. Include address.
13. **ABSTRACT:** Enter an abstract giving a brief and factual summary of the document, even though it may also appear elsewhere in the body of the document itself. It is highly desirable that the abstract of classified documents be unclassified. Each paragraph of the abstract shall end with an indication of the security classification of the information in the paragraph (unless the document itself is unclassified) represented as (TS), (S), (IC), (R), or (U).

The length of the abstract should be limited to 20 single-spaced standard typewritten lines; 7½ inches long.
14. **KEY WORDS:** Key words are technically meaningful terms or short phrases that characterize a document and could be helpful in cataloging the document. Key words should be selected so that no security classification is required. Identifiers, such as equipment model designation, trade name, military project code name, geographic location, may be used as key words but will be followed by an indication of technical context.